Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citrepel is a botanical insect repellent formulation containing 30% Citriodiol, which is a trade name for Oil of Lemon Eucalyptus (OLE). The active ingredient is p-menthane-3,8-diol (PMD), a naturally occurring compound derived from the leaves of the *Eucalyptus citriodora* tree. Developed and manufactured by Citrefine International Ltd, Citrepel is registered with the EPA (Reg. No. 84878-2) and is used topically to provide long-lasting protection against mosquitoes, ticks, and midges. It serves as a natural alternative to synthetic repellents like DEET and has been evaluated in clinical trials for its efficacy in preventing bites from disease-carrying vectors, thereby reducing the risk of vector-borne diseases such as Lyme disease and Malaria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Citrepel.